To determine the ability of KRAS and TP53 VAF to predict total tumor burden, the baseline tumor volume as measured by total RECIST measurements of target lesion diameters (in mm) was compared to baseline KRAS and TP53 VAFs. This evidence concerns the gene KRAS and neoplasm.